Veeva DQS Cleans Data for More Than 1 Million Subjects Across Over 1,000 Studies

Veeva Systems (NYSE: VEEV) announced that its Data Quality System has aggregated and cleaned clinical trial data for more than 1 million subjects.

Rhea-AI Summary

Veeva Systems (NYSE: VEEV) announced that its Data Quality System has aggregated and cleaned clinical trial data for more than 1 million subjects. The platform, known as Veeva DQS, has handled data across more than 1,000 studies and generated more than 500,000 automated queries. Veeva said this automation has saved sites and sponsors thousands of hours in data reconciliation.

Upcoming DQS innovations include automated data exchange with Veeva CTMS for risk-based monitoring and AI-assisted classification of study data. The recently announced Veeva Study Builder Agent configures Veeva EDC and DQS directly from a study protocol.

Key Figures

Subjects with data aggregated and cleaned: More than 1 million subjects Studies covered: More than 1,000 studies Automated queries: More than 500,000 +1 more

Subjects with data aggregated and cleaned

More than 1 million subjects

Veeva DQS

Studies covered

More than 1,000 studies

Veeva DQS

Automated queries

More than 500,000

Veeva DQS

Hours saved

Thousands of hours

Data reconciliation for sites and sponsors

Key Terms

ich e6(r3), risk-based quality management (rbqm), key risk indicators (kris), cros

4 terms

ich e6(r3) regulatory

"recommended in regulatory guidelines, including ICH E6(R3)"

An international regulatory guidance document from the International Council for Harmonisation (ICH) titled "E6(R3) — Good Clinical Practice," which sets principles and expectations for designing, conducting, recording and reporting clinical trials involving human subjects. It spells out roles and responsibilities for sponsors, investigators and ethics committees, and addresses trial quality, data integrity, participant protections and modern practices (for example risk-based quality management, use of digital tools and decentralized elements); the guideline itself is not law but is used by regulators and institutions worldwide to shape binding rules and oversight.

risk-based quality management (rbqm) technical

"Enable risk-based quality management (RBQM)"

Risk-based quality management (RBQM) is a regulatory approach that focuses monitoring and oversight efforts on the most important risks to patient safety and data reliability in clinical development and manufacturing. For investors, RBQM signals that a company is prioritizing regulatory compliance and efficient use of resources—like a mechanic checking the brakes before routine parts—reducing the chance of costly errors, trial delays, or regulatory setbacks.

key risk indicators (kris) technical

"calculate, track, and action key risk indicators (KRIs)"

Quantitative or qualitative metrics tracked by a company to signal changes in its exposure to particular risks; each KRI measures a specific risk area (for example credit, market, operational, liquidity, or compliance risk), has an agreed definition and thresholds, and is monitored regularly so rising values or breached thresholds trigger further investigation or action. KRIs are designed as early-warning indicators — some are ‘leading’ (predicting potential problems) while others are ‘lagging’ (reflecting events that already occurred) — and they require clear ownership, validation, and periodic review because a KRI signals elevated risk but does not by itself prove an outcome will occur.

cros technical

"sponsors and CROs are using Veeva DQS to automate data workflows"

Contract research organizations (CROs) are independent firms hired by drug and medical-device companies to run research tasks such as clinical trials, patient recruitment, lab testing, data management, and regulatory filings. For investors they matter because CROs act like contractors turning a sponsor’s plans into finished work—so their capacity, timelines, costs and quality directly affect how quickly and cheaply a drug or device can move toward approval and revenue.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Automates data reconciliation, saving clinical teams significant cost, time, and effort

PLEASANTON, Calif., Oct. 6, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Veeva DQS (Data Quality System) has aggregated and cleaned data for more than 1 million subjects in more than 1,000 studies to accelerate the delivery of analysis-ready data and trial insights. With more than 500,000 automated queries, Veeva DQS has saved thousands of hours in data reconciliation for sites and sponsors.

"One key area for us is handling the increasing volume of data generated from our growing number of clinical trials," said Ibrahim Kamstrup-Akkaoui, vice president at Novo. "Veeva DQS can help us manage, format, clean, and prepare this data for submission more efficiently."

Veeva DQS enables next-generation clinical data management with advancements essential for adopting the risk-based strategies recommended in regulatory guidelines, including ICH E6(R3). With innovations coming in Veeva DQS, clinical teams can:

• Gain high-quality data faster: Veeva DQS automates data workflows, classifies and visualizes critical data, and drives the orchestration of risk-based actions across the clinical ecosystem while eliminating manual data reconciliation.
  
  
• Enable risk-based quality management (RBQM): Automated data exchange between Veeva DQS and Veeva CTMS streamlines risk-based monitoring by instantly alerting clinical operations teams to key data changes, like protocol deviations, and allowing clinical data teams to calculate, track, and action key risk indicators (KRIs).
• Classify with data- and user-aware AI: Veeva DQS embeds AI to speed up the classification of study data and understand its purpose and criticality. This allows the system to generate items, like reports, listings, or test scripts, and deliver custom user experiences and workflows based on role.

"With increasing data sources and growing protocol complexity, sponsors and CROs are using Veeva DQS to automate data workflows at scale across studies of all sizes," said Pavel Burmenko, lead, Veeva DQS strategy. "Veeva DQS is ushering in next-generation data management, a new level of clinical data innovation that orchestrates risk-based reviews and elevates the role of data managers toward strategic partners."

Recently announced, Veeva Study Builder Agent configures Veeva EDC and Veeva DQS directly from a study protocol for faster and more consistent study builds. Learn more about Study Builder Agent, the SCDM Innovation Award winning Veeva DQS, and how biopharmas are driving clinical data innovation at Veeva R&D and Quality Summit, Oct. 20-21 in Boston. The event is open exclusively to life sciences industry professionals.

About Veeva Systems
Veeva delivers the industry cloud for life sciences with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the fiscal year ended July 31, 2026, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:

Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/veeva-dqs-cleans-data-for-more-than-1-million-subjects-across-over-1-000-studies-302899197.html

SOURCE Veeva Systems